Cargando…

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension

Background: Subcutaneous methylnaltrexone (MNTX), dosed based on body weight, is efficacious and well tolerated in inducing bowel movements in patients with advanced illness and opioid-induced constipation (OIC); however, fixed-dose administration of MNTX may improve ease of administration. Objectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bull, Janet, Wellman, Charles V., Israel, Robert J., Barrett, Andrew C., Paterson, Craig, Forbes, William P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492709/ https://www.ncbi.nlm.nih.gov/pubmed/25973526 http://dx.doi.org/10.1089/jpm.2014.0362

Ejemplares similares

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis
por: Viscusi, Eugene R., et al.
Publicado: (2016)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2015)

Methylnaltrexone in the treatment of opioid-induced constipation
por: Meerveld, Beverley Greenwood-Van, et al.
Publicado: (2008)

Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide
por: Bader, S., et al.
Publicado: (2011)

Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide
por: Clemens, Katri Elina, et al.
Publicado: (2010)

Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial
por: Webster, Lynn R., et al.
Publicado: (2017)

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018)

Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation
por: Farchadi, David, et al.
Publicado: (2023)

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness
por: Mehta, Neel, et al.
Publicado: (2023)

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
por: Deibert, Peter, et al.
Publicado: (2010)

Methylnaltrexone and Naloxone for Opioid-induced Constipation in the Critical Care Setting
por: Saini, Harneel S, et al.
Publicado: (2020)

Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials
por: Shah, Eric D, et al.
Publicado: (2023)

Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose
por: Chamberlain, Bruce H, et al.
Publicado: (2023)

Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies
por: Chamberlain, Bruce H, et al.
Publicado: (2021)

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021)

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2018)

Correction to: The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021)

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone
por: Neefjes, Elisabeth CW, et al.
Publicado: (2014)

Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone
por: Webster, Lynn R, et al.
Publicado: (2018)

Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes
por: Siemens, Waldemar, et al.
Publicado: (2016)

Efficacy and Safety of Methylnaltrexone for the Treatment of Opioid-Induced Constipation: A Meta-analysis of Randomized Controlled Trials
por: Zhang, Ying-Ying, et al.
Publicado: (2021)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]
Publicado: (2018)

Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial
por: Patel, Parind B., et al.
Publicado: (2020)

Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus
por: Viscusi, Eugene R., et al.
Publicado: (2013)

Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist
por: Uritsky, Tanya J.
Publicado: (2019)

Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)
por: Patel, Parind B, et al.
Publicado: (2016)

Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials
por: Mehta, Neel, et al.
Publicado: (2023)

Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis
por: Webster, Lynn R, et al.
Publicado: (2022)

Methylnaltrexone bromide methanol monosolvate
por: Li, Guoqing, et al.
Publicado: (2012)

Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis
por: Nelson, Kirbylee K., et al.
Publicado: (2019)

Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors
por: Singleton, Patrick A, et al.
Publicado: (2010)

Effects of the peripherally acting μ-opioid receptor antagonist methylnaltrexone on acute pancreatitis severity: study protocol for a multicentre double-blind randomised placebo-controlled interventional trial, the PAMORA-AP trial
por: Knoph, Cecilie Siggaard, et al.
Publicado: (2021)

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
por: Jamal, M Mazen, et al.
Publicado: (2015)

Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation
por: Chokhavatia, Sita, et al.
Publicado: (2016)

The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies
por: Brenner, Darren M., et al.
Publicado: (2021)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Abdominal Pain due to Opioid-Induced Constipation
por: Jacobs, Chelsea, et al.
Publicado: (2019)

Opioid-Induced Constipation in Advanced Cancer Patients
por: ALMouaalamy, Nabil
Publicado: (2021)

Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients
por: Rizwan, M. Zeeshan, et al.
Publicado: (2023)

Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Duprey, Matthew S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_us5930b5gmpg8fi3f29qrau8na